A Phase 1 Open Label, Dose Escalation Study to Evaluate the Effect of Four Doses of MAGE-A3/HPV 16 Trojan Peptides 0001 and 0002 Administered Subcutaneously

Trial Profile

A Phase 1 Open Label, Dose Escalation Study to Evaluate the Effect of Four Doses of MAGE-A3/HPV 16 Trojan Peptides 0001 and 0002 Administered Subcutaneously

Discontinued
Phase of Trial: Phase I

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Biropepimut-S; Human papillomavirus-16 peptide vaccine
  • Indications Head and neck cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 28 Oct 2015 Status changed from recruiting to discontinued according to results published in the Cancer Immunology Immunotherapy
    • 23 Jul 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top